Johnson & Johnson SG&A Expenses 2010-2024 | JNJ
Johnson & Johnson annual/quarterly sg&a expenses history and growth rate from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Johnson & Johnson sg&a expenses for the quarter ending March 31, 2024 were $5.257B, a 14.35% decline year-over-year.
- Johnson & Johnson sg&a expenses for the twelve months ending March 31, 2024 were $20.631B, a 0.9% increase year-over-year.
- Johnson & Johnson annual sg&a expenses for 2023 were $21.512B, a 6.25% increase from 2022.
- Johnson & Johnson annual sg&a expenses for 2022 were $20.246B, a 0.64% increase from 2021.
- Johnson & Johnson annual sg&a expenses for 2021 were $20.118B, a 8.9% decline from 2020.
Johnson & Johnson Annual SG&A Expenses
(Millions of US $) |
| 2023 |
$21,512 |
| 2022 |
$20,246 |
| 2021 |
$20,118 |
| 2020 |
$22,084 |
| 2019 |
$22,178 |
| 2018 |
$22,540 |
| 2017 |
$21,520 |
| 2016 |
$20,067 |
| 2015 |
$21,203 |
| 2014 |
$21,954 |
| 2013 |
$21,830 |
| 2012 |
$20,869 |
| 2011 |
$20,969 |
| 2010 |
$19,424 |
| 2009 |
$19,801 |
Johnson & Johnson Quarterly SG&A Expenses
(Millions of US $) |
| 2024-03-31 |
$5,257 |
| 2023-12-31 |
$3,309 |
| 2023-09-30 |
$5,400 |
| 2023-06-30 |
$6,665 |
| 2023-03-31 |
$6,138 |
| 2022-12-31 |
$3,107 |
| 2022-09-30 |
$4,975 |
| 2022-06-30 |
$6,226 |
| 2022-03-31 |
$5,938 |
| 2021-12-31 |
$2,613 |
| 2021-09-30 |
$6,000 |
| 2021-06-30 |
$6,073 |
| 2021-03-31 |
$5,432 |
| 2020-12-31 |
$6,457 |
| 2020-09-30 |
$5,431 |
| 2020-06-30 |
$4,993 |
| 2020-03-31 |
$5,203 |
| 2019-12-31 |
$6,039 |
| 2019-09-30 |
$5,374 |
| 2019-06-30 |
$5,546 |
| 2019-03-31 |
$5,219 |
| 2018-12-31 |
$5,991 |
| 2018-09-30 |
$5,543 |
| 2018-06-30 |
$5,743 |
| 2018-03-31 |
$5,263 |
| 2017-12-31 |
$6,045 |
| 2017-09-30 |
$5,423 |
| 2017-06-30 |
$5,289 |
| 2017-03-31 |
$4,763 |
| 2016-12-31 |
$5,431 |
| 2016-09-30 |
$4,772 |
| 2016-06-30 |
$5,176 |
| 2016-03-31 |
$4,688 |
| 2015-12-31 |
$5,891 |
| 2015-09-30 |
$5,081 |
| 2015-06-30 |
$5,384 |
| 2015-03-31 |
$4,847 |
| 2014-12-31 |
$5,822 |
| 2014-09-30 |
$5,468 |
| 2014-06-30 |
$5,481 |
| 2014-03-31 |
$5,183 |
| 2013-12-31 |
$5,917 |
| 2013-09-30 |
$5,314 |
| 2013-06-30 |
$5,376 |
| 2013-03-31 |
$5,223 |
| 2012-12-31 |
$5,661 |
| 2012-09-30 |
$5,228 |
| 2012-06-30 |
$4,965 |
| 2012-03-31 |
$5,015 |
| 2011-12-31 |
$5,458 |
| 2011-09-30 |
$5,240 |
| 2011-06-30 |
$5,215 |
| 2011-03-31 |
$5,056 |
| 2010-12-31 |
$5,180 |
| 2010-09-30 |
$4,709 |
| 2010-06-30 |
$4,756 |
| 2010-03-31 |
$4,779 |
| 2009-12-31 |
$5,629 |
| 2009-09-30 |
$4,767 |
| 2009-06-30 |
$4,797 |
| 2009-03-31 |
$4,608 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$360.785B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
